WO2002089586A1 - Lignee cellulaire epitheliale pulmonaire pour propagation de virus - Google Patents
Lignee cellulaire epitheliale pulmonaire pour propagation de virus Download PDFInfo
- Publication number
- WO2002089586A1 WO2002089586A1 PCT/US2002/015030 US0215030W WO02089586A1 WO 2002089586 A1 WO2002089586 A1 WO 2002089586A1 US 0215030 W US0215030 W US 0215030W WO 02089586 A1 WO02089586 A1 WO 02089586A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- influenza
- virus
- cells
- cell line
- viruses
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 229
- 210000002919 epithelial cell Anatomy 0.000 title claims abstract description 73
- 210000004072 lung Anatomy 0.000 title claims abstract description 71
- 230000001902 propagating effect Effects 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 382
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 179
- 206010022000 influenza Diseases 0.000 claims abstract description 123
- 229960005486 vaccine Drugs 0.000 claims abstract description 118
- 230000010076 replication Effects 0.000 claims abstract description 50
- 101710154606 Hemagglutinin Proteins 0.000 claims abstract description 37
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims abstract description 37
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims abstract description 37
- 101710176177 Protein A56 Proteins 0.000 claims abstract description 37
- 239000000185 hemagglutinin Substances 0.000 claims abstract description 37
- 241001465754 Metazoa Species 0.000 claims abstract description 29
- 230000000890 antigenic effect Effects 0.000 claims abstract description 29
- 238000004113 cell culture Methods 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 208000015181 infectious disease Diseases 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 51
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 241000282414 Homo sapiens Species 0.000 claims description 32
- 239000000427 antigen Substances 0.000 claims description 29
- 102000036639 antigens Human genes 0.000 claims description 29
- 108091007433 antigens Proteins 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 25
- 239000002671 adjuvant Substances 0.000 claims description 18
- 230000002238 attenuated effect Effects 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 241000283073 Equus caballus Species 0.000 claims description 16
- 230000002458 infectious effect Effects 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000013612 plasmid Substances 0.000 claims description 13
- 206010064097 avian influenza Diseases 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 9
- 238000001890 transfection Methods 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 7
- 208000002979 Influenza in Birds Diseases 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000006143 cell culture medium Substances 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000000644 propagated effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 244000144977 poultry Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 58
- 235000013601 eggs Nutrition 0.000 abstract description 44
- 241000287828 Gallus gallus Species 0.000 abstract description 31
- 229960004854 viral vaccine Drugs 0.000 abstract description 10
- 239000000356 contaminant Substances 0.000 abstract description 9
- 230000008093 supporting effect Effects 0.000 abstract description 5
- 230000009447 viral pathogenesis Effects 0.000 abstract description 2
- 230000003612 virological effect Effects 0.000 description 63
- 235000013330 chicken meat Nutrition 0.000 description 30
- 150000007523 nucleic acids Chemical class 0.000 description 26
- 230000006907 apoptotic process Effects 0.000 description 24
- 230000012010 growth Effects 0.000 description 24
- 102000039446 nucleic acids Human genes 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 23
- 108020003175 receptors Proteins 0.000 description 21
- 102000005962 receptors Human genes 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 19
- 241000282898 Sus scrofa Species 0.000 description 19
- 229960003971 influenza vaccine Drugs 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 241000712431 Influenza A virus Species 0.000 description 18
- 150000001413 amino acids Chemical group 0.000 description 18
- 239000002609 medium Substances 0.000 description 18
- 210000002845 virion Anatomy 0.000 description 17
- 108010006232 Neuraminidase Proteins 0.000 description 16
- 230000028993 immune response Effects 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 230000009385 viral infection Effects 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 230000001717 pathogenic effect Effects 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 102000005348 Neuraminidase Human genes 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 239000012588 trypsin Substances 0.000 description 14
- 241000271566 Aves Species 0.000 description 13
- 102000004142 Trypsin Human genes 0.000 description 13
- 108090000631 Trypsin Proteins 0.000 description 13
- 101150008103 hal gene Proteins 0.000 description 13
- 208000037797 influenza A Diseases 0.000 description 13
- 230000001681 protective effect Effects 0.000 description 11
- 230000000120 cytopathologic effect Effects 0.000 description 10
- 241001493065 dsRNA viruses Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 208000037798 influenza B Diseases 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 230000029812 viral genome replication Effects 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 241000881705 Porcine endogenous retrovirus Species 0.000 description 9
- 108010067390 Viral Proteins Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 230000005180 public health Effects 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 102000011931 Nucleoproteins Human genes 0.000 description 8
- 108010061100 Nucleoproteins Proteins 0.000 description 8
- 108700005077 Viral Genes Proteins 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000000241 respiratory effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000114864 ssRNA viruses Species 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108090000288 Glycoproteins Proteins 0.000 description 7
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 7
- 206010028851 Necrosis Diseases 0.000 description 7
- 241000772415 Neovison vison Species 0.000 description 7
- 241000712464 Orthomyxoviridae Species 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 230000017074 necrotic cell death Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 239000002023 wood Substances 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 108090000672 Annexin A5 Proteins 0.000 description 5
- 102000004121 Annexin A5 Human genes 0.000 description 5
- 102000009016 Cholera Toxin Human genes 0.000 description 5
- 108010049048 Cholera Toxin Proteins 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000711950 Filoviridae Species 0.000 description 5
- 102100034343 Integrase Human genes 0.000 description 5
- 108010057466 NF-kappa B Proteins 0.000 description 5
- 102000003945 NF-kappa B Human genes 0.000 description 5
- 241000711504 Paramyxoviridae Species 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- 241000711931 Rhabdoviridae Species 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 210000003292 kidney cell Anatomy 0.000 description 5
- -1 phosphate ester Chemical class 0.000 description 5
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 241000701242 Adenoviridae Species 0.000 description 4
- 101710186708 Agglutinin Proteins 0.000 description 4
- 235000006576 Althaea officinalis Nutrition 0.000 description 4
- 241000534454 Arenaria interpres Species 0.000 description 4
- 241000712892 Arenaviridae Species 0.000 description 4
- 241000702628 Birnaviridae Species 0.000 description 4
- 241000272161 Charadriiformes Species 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 4
- 241000710781 Flaviviridae Species 0.000 description 4
- 241000700586 Herpesviridae Species 0.000 description 4
- 101710146024 Horcolin Proteins 0.000 description 4
- 241000701377 Iridoviridae Species 0.000 description 4
- 101710189395 Lectin Proteins 0.000 description 4
- 101710179758 Mannose-specific lectin Proteins 0.000 description 4
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 4
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 4
- 241000701945 Parvoviridae Species 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 241000150350 Peribunyaviridae Species 0.000 description 4
- 241000709664 Picornaviridae Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 241000700625 Poxviridae Species 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 241000702247 Reoviridae Species 0.000 description 4
- 241000712907 Retroviridae Species 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 241000710924 Togaviridae Species 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 108700010877 adenoviridae proteins Proteins 0.000 description 4
- 239000000910 agglutinin Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 4
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 210000001840 diploid cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 210000000605 viral structure Anatomy 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000272814 Anser sp. Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000700739 Hepadnaviridae Species 0.000 description 3
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 108091034135 Vault RNA Proteins 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- 102000018265 Virus Receptors Human genes 0.000 description 3
- 108010066342 Virus Receptors Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000004779 membrane envelope Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 244000105975 Antidesma platyphyllum Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 2
- 102000010579 Fas-Associated Death Domain Protein Human genes 0.000 description 2
- 108010077716 Fas-Associated Death Domain Protein Proteins 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 101150039660 HA gene Proteins 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 229940124873 Influenza virus vaccine Drugs 0.000 description 2
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 2
- 241001521394 Maackia amurensis Species 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000010359 Newcastle Disease Diseases 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000202347 Porcine circovirus Species 0.000 description 2
- 208000009341 RNA Virus Infections Diseases 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 240000006028 Sambucus nigra Species 0.000 description 2
- 235000003142 Sambucus nigra Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 241000725681 Swine influenza virus Species 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 241000710886 West Nile virus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000005574 cross-species transmission Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 229960003239 encephalitis vaccine Drugs 0.000 description 2
- 235000008995 european elder Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 235000009424 haa Nutrition 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002434 immunopotentiative effect Effects 0.000 description 2
- 238000012606 in vitro cell culture Methods 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 208000037799 influenza C Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229960001226 live attenuated influenza Drugs 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 229940041323 measles vaccine Drugs 0.000 description 2
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229940095293 mumps vaccine Drugs 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012342 propidium iodide staining Methods 0.000 description 2
- 239000013014 purified material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002976 reverse transcriptase assay Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960001515 yellow fever vaccine Drugs 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 102000007272 Apoptosis Inducing Factor Human genes 0.000 description 1
- 108010033604 Apoptosis Inducing Factor Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241000231690 Ardenna pacifica Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000004046 Caspase-2 Human genes 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- 102000004091 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 101710089384 Extracellular protease Proteins 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 241000197304 H2N2 subtype Species 0.000 description 1
- 241000252870 H3N2 subtype Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000134304 Influenza A virus H3N2 Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000713174 Influenza B virus (B/Ann Arbor/1/1966 [wild- type]) Species 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000282331 Mustelidae Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241001415846 Procellariidae Species 0.000 description 1
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 240000001068 Thogoto virus Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 208000003836 bluetongue Diseases 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- MXCPYJZDGPQDRA-UHFFFAOYSA-N dialuminum;2-acetyloxybenzoic acid;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3].CC(=O)OC1=CC=CC=C1C(O)=O MXCPYJZDGPQDRA-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 108700010900 influenza virus proteins Proteins 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 235000020130 leben Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 108091011000 phospholipid binding proteins Proteins 0.000 description 1
- 102000036213 phospholipid binding proteins Human genes 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 208000005814 piedra Diseases 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000009862 superficial mycosis Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960000172 trivalent influenza vaccine Drugs 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
- C12N2760/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Definitions
- the present invention relates to a novel lung epithelial cell line, which supports efficient replication of viruses, particularly influenza viruses.
- Influenza Virus is the most frequent cause of acute respiratory illness requiring medical intervention because it affects all age groups and because it can recur in any individual. Influenza (in particular, certain influenza A and B subtypes) is a severe cause of morbidity and mortality throughout the world, resulting in annual outbreaks in all age ranges of the population.
- Pandemics are the result of novel virus subtypes of influenza A, created by reassortment of the segmented genome (antigenic shift), whereas annual epidemics are the result of evolution of the surface antigens of influenza A and B virus (antigenic drift).
- Human influenza viruses originate from avian strains of influenza virus so that influenza infection is at its basis a zoonosis. There is evidence that pigs can serve as an intermediate host ("mixing vessel") for the generation of new avian-originated strains that are pathogenic in humans (Scholtissek et al., Virology 1985,
- influenza A outbreak in Hong Kong in 1997 showed that highly pathogenic influenza A viruses can also be transmitted directly from avian species to humans (Claas et al. , Lancet 1998, 351 :472; Suarez et al, J.Virol. 1998, 72:6678; Subbarao et al, Science 1998, 279:393; Shortridge, Vaccine 1999, 17 (Suppl. 1): S26-S29).
- the potential of influenza A viruses to generate new pathogenic strains from a vast number of circulating strains in the natural reservoir indicates that disease control requires monitoring these viruses and developing improved antiviral therapies and vaccines. The speed with which new strains develop demands vigilance in this monitoring effort, and stretches the capacity of current technology to produce sufficient quantities of vaccine against a newly identified pathogenic strain to prevent an epidemic or pandemic.
- Influenza A, B and C, of the family Orthomyxoviridae all have a segmented negative strand RNA genome that is replicated in the nucleus of the infected cell, has a combined coding capacity of about 13 kb, and contains the genetic information for ten viral proteins.
- influenza viruses have eight negative-sense RNA (nsRNA) gene segments that encode at least 10 polypeptides, including RNA-directed RNA polymerase proteins (PB2, PBl and PA), nucleoprotein (NP), neuraminidase (NA), hemagglutinin (association of subunits HAl and HA2), the matrix proteins (Ml and M2) and the non-structural proteins (NS1 and NS2) (Krug et al., In The Influenza Viruses, R.M. Krug, ed., Plenum Press, New York, 1989, pp. 89-152).
- PB2, PBl and PA RNA-directed RNA polymerase proteins
- NP nucleoprotein
- NA neuraminidase
- hemagglutinin association of subunits HAl and HA2
- Ml and M2 matrix proteins
- NS1 and NS2 non-structural proteins
- vRNAs negative-sense viral RNAs
- PBl viral polymerase complex proteins
- PA viral polymerase complex proteins
- NP viral polymerase complex proteins
- the body of the influenza virus has a size of about 125 nm and consists of a core of nsRNAs associated with the nucleoprotein, surrounded by a viral envelope with a lipid bilayer structure.
- the inner layer of the viral envelope is composed predominantly of matrix proteins and the outer layer contains most of the host-derived lipid material.
- Infectivity of novel influenza viruses depends on the cleavage of HA by specific host proteases, whereas NA is involved in the release of progeny virions from the cell surface and prevents clumping of newly formed virus.
- the virus causes gastrointestinal infection.
- replication of influenza subtypes appears restricted to respiratory epithelial cells.
- the HA and NA proteins embedded in the viral envelope are the primary antigenic determinants of the influenza virus (Air et al., Structure, Function, and Genetics, 1989, 6:341-356; Wharton et al, In The Influenza Viruses, R. M. Krug, ed., Plenum Press, New York, 1989, pp. 153-174). Due to reassortment of influenza segmented genome, new HA and NA variants are constantly created for which a newly infected organism has no anamnestic immune response.
- HlNl Of the 15 HA and 9 NA subtypes of influenza circulating in aquatic birds, three, HlNl , H2N2, and H3N2 subtypes are known to have caused pandemics in humans (Webster et al., Microbiol. Rev. 1992, 56:152).
- HA glycoprotein is the major antigen for neutralizing antibodies and is involved in the binding of virus particles to receptors on host cells.
- HA is synthesized in infected cells as a single polypeptide.
- Post-translational protease cleavage of the precursor HA results in the formation of the two subunits, HAl and HA2, joined by a disulfide bond.
- Cleavage is essential for production of infectious viruses: virions containing uncleaved HA are noninfectious. The cleavage process can occur intracellularly or extracellularly.
- HAs of infectious viruses are cleaved by extracellular proteases, such as from intestinal bacteria or the pancreas in vivo
- the HAs of human, porcine and most avian influenza virus strains cannot be cleaved by intracellular proteases. Therefore, replication of these viruses in many cell cultures requires the addition of a protease (such as trypsin) to the maintenance medium to ensure HA cleavage, thereby permitting activation of the progeny virus so that the rounds of infection can continue (see below).
- a protease such as trypsin
- influenza vaccines currently licensed by public health authorities for use in the United States and Europe are inactivated influenza vaccines.
- the viruses presenting epidemiologically important influenza A and influenza B strains are grown in embryonated chicken eggs and the virus particles are subsequently purified and inactivated by chemical means.
- Each year the WHO selects subtypes which most likely will circulate: currently two strains for influenza A (HlNl) and (H3N2), and a B strain.
- influenza vaccines have been in use since the early 1940's for human vaccination and since the late 1960's for equine vaccination, the existence of an extensive animal reservoir, combined with the threat of emergence of a novel influenza virus capable of causing a pandemic, has spurred research into novel therapies with which to fight the virus.
- Several important advances in the field of influenza have occurred in the last few years (reviewed in Cox and Subbarao, Lancet 1999, 354: 1277-82).
- an experimental live, attenuated, intranasally administered trivalent influenza vaccine was shown to be highly effective in protecting young children against influenza A H3N2 and influenza B.
- New antiviral drugs such as amantadine HCl and drugs based on the structure of the NA molecule were assessed in clinical trials and found to be effective against influenza A and B viruses.
- Other approaches to improve the efficacy of the current (killed) influenza virus vaccines include the generation of cold-adapted and genetically engineered influenza viruses containing specific attenuating mutations (reviewed in Palese et al, J. Infect. Dis., 1997, 176 Suppl 1 :S45-9). It is hoped that these genetically altered viruses, in which the HA and NA genes from circulating strains have been incorporated by reassortment, can be used as safe live influenza virus vaccines to induce a long-lasting protective immune response in humans.
- genetically engineered influenza viruses may provide a means for expressing foreign antigens.
- Curmetly employed influenza vaccines are based either on live virus or "killed” or “inactivated” virus. Most of the commercially available inactivated influenza vaccines are so-called “split vaccines” or “subunit vaccines". "Split vaccines” are prepared by the treatment of the whole influenza virus with solubilizing concentrations of detergents and subsequent removal of the detergent and of the bulk of the viral lipid material. "Subunit vaccines” against influenza unlike “split vaccines” do not contain all viral proteins. Instead, “subunit vaccines” are enriched in surface proteins responsible for eliciting the desired virus neutralizing (hence protecting) antibodies upon vaccination.
- the reassorted influenza virus is then grown in embryonated chicken eggs, purified from virus-containing allantoic fluid of the eggs and subsequently inactivated and standardized for use as vaccines.
- embryonated chicken eggs have potentially serious limitations as a host system due to (i) the varying (micro)biological quality of the eggs because of the presence of adventitious agents (e.g., other viruses); (ii) the lack of reliable year-around supplies of high-quality eggs (e.g., caused by the low susceptibility of summer eggs to influenza virus infection [Monto et al, J. Clin. Microb., 1981, 13:233-235]); (iii) the lack of production flexibility if suddenly demand increases, i.e., in case of a serious epidemic or pandemic, because of the logistic problems due to non-availability of large quantities of suitable eggs; (iv) known hypersensitivity to chicken and/or egg proteins in many subjects.
- tissue culture production of influenza virus may reside in tissue culture production of influenza virus.
- tissue culture cell lines are available in well-defined cell bank systems free of microbiological contaminants, whereby the batch-to-batch consistency is greatly improved and a product of higher quality is obtained;
- use of tissue culture-based virus production increases the ability to have sufficient vaccine available in case of a serious epidemic or pandemic threat;
- the resulting influenza virus material is better suited for alternative routes of administration (oral, nasal, inhaled);
- the yearly vaccine composition recommendation can be pushed back from mid-February to mid-March, improving the efficiency of identifying the circulating pathogenic strains and creating appropriate vaccines.
- Various cultured mammalian cells have been used for virus replication.
- CCLs Continuous cell lines
- influenza production was attained in primary diploid cell cultures derived from human adenoid, rhesus monkey kidneys (Endo et al, J. Virol., 1996, 70:2055-2058;
- monkey kidney cells obtained from wild animals usually contain endogenous viruses (Grachev, In Guidance for the Production of Vaccines and Sera., Burgasov, ed., Medicine, Moscow, p 176, 1978; Grachev, Zh. Microbiol. Epidemiol. Immunobiol., 1987, 2:76), while mink lung cells are highly unstable in culture (Schultz-Cherry et al, 1998. J. Clin. Microbiol. 36:3718-3720).
- Influenza virus propagation has been also demonstrated in primary cell cultures of Chicken Embryo Fibroblasts (CEF), however, viral titers produced in these cultures are very low (Maassab, Proc. Natl. Acad. Sci. USA, 1959, 45: 1035-1039).
- the advantages of using continuous cell lines are their retention of original antigenic characteristics of the infected virus, easy standardization, high susceptibility to variants of the same virus, and ability to be grown as a large mass of cells using microcarrier or suspension fermentor systems (Mizrahi, ed., Viral Vaccines, Wiley-Liss, New York, 1990, pp. 39-67; Katz et al, Virology, 1988, 165:446-456; Robertson et al, Virology, 1990, 179:35-40; Katz et al, J. Infect. Dis., 1989, 160:191-198; Wood et al, Virology, 1989, 171 :214-221).
- African green monkey kidney cells Vero; see, e.g., U.S. Patent No. 5,824,536
- baby hamster kidney cells BHK-21
- WHO World Health Organization
- influenza B in Vero cells appears to be greatly restricted as compared to MDCK cells (Nakamura et al, J. Gen. Virol., 1981, 56:199-202), while influenza growth in BHK cells, like that in eggs, results in the selection of receptor-binding variants (Govorkova et al, Virology, 1999, 262;31-38).
- Another potentially useful cell line, MRC-5 has extremely stringent growth media requirements making it suboptimal for large-scale production of influenza viruses for use in vaccines.
- influenza infection of epithelial cells such as MDCK or HeLa cells leads to programmed cell death (apoptosis)
- apoptosis programmed cell death
- the porcine lung epithelial cell line of the present invention supports replication of all tested avian, swine, equine, and human isolates of influenza A viruses as well as all tested human isolates of influenza B viruses and is useful not only for the production of influenza vaccine, but also for production of various other viruses as well as in viral surveillance and in the study of viral pathogenesis, factors that influence interspecies transmission, and virus-induced cell damage.
- an epithelial cell line particularly a lung epithelial cell line, and more particularly a porcine lung epithelial cell line, that has acceptable virus production characteristics.
- this cell line (i) supports the high titer replication of all subtypes of influenza viruses, (ii) maintains antigenic properties of the clinical isolates of the natural virus, and (iii) avoids having significant adventitious agents present in final viral preparations, which are unsuitable for vaccine production.
- Such a cell line preferably has the characteristics of porcine lung epithelial cell line SJPL.
- propagation of influenza viruses in an epithelial cell line of the instant invention is not accompanied by antigenic changes in the HAl region of the hemagglutinin molecule and is free of contaminants which are potentially harmful for vaccine production.
- the porcine lung epithelial cell line of the present invention is SJPL cell line deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, USA on April 5, 2001, and assigned Accession No. PTA-3256.
- ATCC American Type Culture Collection
- a novel lung epithelial cell line of the invention is useful, ter alia, for studying the influenza infection and propagation, virus surveillance, isolating functional components of influenza virus, and for sensitive, fast diagnostic and therapeutic applications.
- the present invention also provides a method for the preparation of influenza virus or virus-derived antigen(s) in cell culture comprising transfecting or infecting the lung epithelial cell line of the invention with the influenza virus or its derivatives (and may further comprise isolation and purification of the propagated viral particles and/or antigens).
- the present invention allows for a high titer viral production, resulting in viral titers of at least 3 x IO 7 plaque forming units (PFU) per ml, preferably 5 x IO 7 PFU/ ml.
- influenza virus propagation in the lung epithelial cell line of the invention is not accompanied by antigenic changes in the HAl region of the influenza hemagglutinin (HA) molecule.
- viral preparations produced according to the method disclosed herein may be applied during the production of vaccines containing diverse influenza virus strains such as the viruses typical for human influenza, porcine influenza, equine influenza, and avian influenza.
- the instant invention also provides isolated viral particles, viral antigens and virus-based vaccine preparations (the latter further comprising a pharmaceutically acceptable carrier or diluent and/or adjuvant) produced in the cell line of the invention.
- the viral preparations of the invention can be either infectious, non-infectious, or attenuated.
- the present invention further advantageously provides a method for preventing an influenza infection in an animal (e.g. , human, porcine, equine, or avian) comprising administering to the animal vaccine compositions produced using the lung epithelial cell line of the invention according to the methods disclosed above.
- an animal e.g. , human, porcine, equine, or avian
- the invention also provides a method of screening for anti-influenza therapeutics comprising administering a candidate agent to the influenza- producing lung epithelial cell line of the invention and testing for change in the level of influenza replication or influenza-associated protein expression compared to the control untreated cell line.
- influenza virus infection of porcine lung epithelial cells does not lead to apoptosis as does infection of MDCK cells.
- the invention By providing a method for producing influenza-derived antigens in lung epithelial cells, the invention also provides a method for producing novel polyclonal antibodies to influenza-derived proteins and/or viral particles.
- the novel anti -influenza antibodies disclosed herein may be used diagnostically, e.g., to detect the presence and/or propagation of influenza in a cell culture or in an animal. Alternatively, these antibodies may be used therapeutically, e.g., in passive immunotherapy.
- the invention also provides a test kit for influenza diagnostics comprising anti-influenza antibodies, influenza virus components and the lung epithelial cell line permissive for influenza replication and expressing these components.
- the lung epithelial cell line of the invention can be also used for production of various viruses, viral components, and anti-viral vaccines that are unrelated to influenza. Accordingly, the scope of the present invention extends to production in the cell line of the invention of all viruses, viral components, and anti-viral vaccines, including, but not limited to, negative strand ssRNA viruses (such as Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, and Filoviridae), ambisense ssRNA viruses (such as Bunyaviridae and Arenaviridae), positive strand ssRNA viruses (such as Picornaviridae, Calciviridae, Togaviridae, Flaviviridae, Coronaviridae, and Retroviridae), dsRNA viruses (such as Reoviridae and Birnaviridae), and DNA viruses (such as Hepadnavi idae, Parvoviridae, Papovaviridae,
- non-influenza anti-viral vaccines of the invention for human and animal use include without limitation parainfluenza vaccines, ebola virus vaccines, West Nile virus vaccines, respiratory syncitial virus vaccines, measles vaccines, mumps vaccines, yellow fever vaccines, hepatitis A and B vaccines, herpes vaccines, foot-and-mouth disease vaccines, Newcastle disease vaccines, porcine circovirus vaccines, and equine encephalitis vaccines.
- the present invention advantageously provides a novel stable lung epithelial cell line, particularly a porcine lung epithelial cell line, which, upon transfection or infection, can support high titer replication of various viruses, such as (but not limited to) ambisense ssRNA viruses (e.g., Bunyaviridae and Arenaviridae), positive strand ssRNA viruses (e.g., Picornaviridae, Calciviridae, Togaviridae, Flaviviridae, Coronaviridae, and Retroviridae), dsRNA viruses (e.g., Reoviridae and Birnaviridae), DNA viruses (e.g., Hepadnaviridae, Parvoviridae, Papovaviridae, Adenoviridae, Herpesviridae, Poxviridae, and Iridoviridae) and, in particular, negative strand RNA viruses (e.g., Orthomyxoviridae, Paramyx
- the invention is based, in part, on the discovery of a spontaneous porcine lung epithelial cell line, and the ability of this cell line to propagate high titers of influenza virus.
- propagation of influenza viruses in the lung epithelial cell line of the invention is not accompanied by antigenic changes in the HAl region of the hemagglutinin (HA) molecule and is free of contaminants which are potentially harmful for vaccine production.
- influenza virus infection of porcine lung epithelial cells does not lead to apoptosis, as it does in MDCK cells.
- the porcine lung epithelial cell line of the present invention is cell line SJPL deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, USA on April 5, 2001, and assigned Accession No. PTA-3256.
- ATCC American Type Culture Collection
- the invention is also based on a further discovery of a chicken lung epithelial cell line that has improved influenza virus replication properties compared to embryonated eggs and MDCK cells.
- virions or virus-derived antigens from the lung epithelial cell line of the present invention for vaccine production.
- These virions or antigens can be generated for the purpose of providing a recombinant attenuated anti-virus vaccine.
- the virus is influenza virus.
- the present invention provides (i) in vitro cell culture model of virus propagation (useful, e.g., to identify and study factors that influence interspecies transmission and virus-induced cell damage); (ii) system for screening candidate anti-viral compounds and evaluating drug resistance; (iii) methods for diagnosing viral infection; and (iv) system for production of large quantities of virus-derived components or recombinant viral particles for antibody generation and/or vaccine development.
- a novel cell line of the invention preferably has the characteristics of cell line SJPL (ATCC Accession No.
- a cell line has the influenza virus propagation characteristics of SJPL when it produces high titers of virus, and thus does not have to produce the same viral titers as described in the Examples, infra.
- a cell line has a characteristic of SJPL when it does not undergo apoptosis when infected by influenza virus.
- One such characteristic of a cell line of the invention is that it yields final viral preparations that are free of adventitious agents that are unsuitable for vaccine production.
- adventitious agents are contaminants, including, but not limited to, bacteria, other viruses, mycoplasma, host genome-derived fragments (e.g., encoding oncogenes), and prions.
- Various health authorities set standards for acceptable vaccines, and a characteristic of a cell line of the invention is in compliance with such standards as set forth by one or more of the following public health authorities: the World Health Organization, the United States Food and Drug Administration, Public Health Agency of any State of the United States (such as, but not limited to, California, Massachusetts, and New York), the Health and Consumer Protection Directorate-General of the European Commission, Health Canada Population and Public Health Branch, Japanese Public Health Association, Australian Department of Health and Aged Care.
- a cell line of the invention is a lung epithelial cell line; (ii) is spontaneously generated; (iii) is continuous, i.e., able to propagate indefinitely in tissue culture; (iv) is morphologically similar to SJPL; (v) produces high titers of virus; and (vi) is free of adventitious agents.
- pathogenic virus strain is used herein to refer to any virus strain that is capable of causing disease; preferably, the virus is on the current World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), or other public health authority list of likely circulating viruses.
- WHO World Health Organization
- CDC Centers for Disease Control and Prevention
- Such viruses may include (but are not limited to), e.g., members of the Orthomyxoviridae family, the Paramyxoviridae family, the Rhabdoviridae family, the Filoviridae family, the Bunyaviridae family, the Arenaviridae family, the Birnaviridae family, the Reoviridae family, the Togaviridae family, the Flaviviridae family, the Coronaviridae family, the Picornaviridae family, the Calciviridae family, the Retroviridae family, the Hepadnaviridae family, the Parvoviridae family, the Papovaviridae family, the Adenoviridae family, the Herpesviridae family, the Poxviridae family, or the Iridoviridae family.
- members of the Orthomyxoviridae family the Paramyxoviridae family, the Rhabdoviridae family, the Filoviridae family, the Bunyavi
- a “negative strand RNA virus” is a virus in which the viral genome consists of “negative strand RNA” or “nsRNA” or “vRNA”, wherein viral or virus-derived polypeptides are encoded by the "positive strand RNA” or “cRNA” which is complementary to the genome.
- Negative strand RNA virus families include, but are not limited to, Orthomyxoviridae,
- the viral genome is from a virus that is a member of the Orthomyxoviridae virus family, and optimally has a segmented genome.
- Members of the Orthomyxovirdae virus family include, but are not limited to, influenza A, influenza B, influenza C, and Thogotovirus.
- the term "negative strand RNA virus virions" refers to the viral particles
- vRNA and viral proteins which when first produced are fully infectious.
- influenza virus is used herein to define a viral species of which pathogenic strains cause the disease known as influenza or flu.
- viral RNA which includes influeza RNA, refers to RNA from the viral genome, fragments thereof, transcripts thereof, and mutant sequences derived therefrom.
- a "viral gene segment” is a cDNA corresponding to a genomic RNA molecule from a segmented (discontinuous) negative strand RNA virus genome.
- purified influenza virions refers to a preparation of influenza viral or virus-like particles that have been isolated from the cellular constituents with which the virus normally associates, and from other types of viruses that may be present in the infected tissue.
- the techniques for isolating viruses are known to those of skill in the art, and include, for example, centrifugation and affinity chromatography.
- nucleic acid molecule refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules”) or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules”), in either single stranded form, or a double-stranded form. Double stranded DNA-DNA, DNA-RNA and RNA-RNA duplexes are possible.
- nucleic acid molecule refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. In discussing the structure of particular nucleic acid molecules, sequences or regions may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction.
- a "recombinant nucleic acid molecule” is a nucleic acid molecule that has undergone a molecular biological manipulation.
- a "coding sequence” or a sequence “encoding” an expression product such as a RNA, polypeptide, protein, or enzyme, is a nucleotide sequence that, when expressed, results in the production of that RNA, polypeptide, protein, or enzyme, i.e., the nucleotide sequence encodes an amino acid sequence for that polypeptide, protein or enzyme.
- translation of influenza-derived (+) strand RNA yields functional viral proteins.
- viral gene means a DNA or RNA sequence that codes for or corresponds to a particular sequence of amino acids which comprise all or part of one or more viral proteins or enzymes.
- express and expression mean allowing or causing the information in a gene or nucleic acid sequence to become manifest, for example producing an RNA or protein by activating the cellular functions involved in transcription and translation of a corresponding gene or nucleic acid sequence.
- a nucleic acid sequence is expressed in or by a cell to form an "expression product" such as mRNA or a protein.
- the expression product itself, e.g. the resulting protein, may also be said to be “expressed” by the cell.
- transfection means the introduction of a foreign nucleic acid into a cell so that the host cell will express the introduced gene or sequence to produce a desired polypeptide, coded by the introduced gene or sequence.
- the introduced gene or sequence may also be called a “cloned” or “foreign” gene or sequence, may include regulatory or control sequences, such as start, stop, promoter, signal, secretion, or other sequences used by a cell's genetic machinery.
- the gene or sequence may include nonfunctional sequences or sequences with no known function.
- a host cell that receives and expresses introduced DNA or RNA has been "transformed” and is a "transformant” or a “clone.”
- the DNA or RNA introduced to a host cell can come from any source, including cells of the same genus or species as the host cell, or cells of a different genus or species.
- vector means the vehicle by which a DNA or RNA sequence (e.g. a foreign gene) can be introduced into a host cell, so as to transform the host and promote expression (e.g. transcription and translation) of the introduced sequence.
- Plasmids are preferred vectors of the invention.
- polypeptide refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to, or exclude, post- translational modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations, and the like.
- chimeric is used herein in its usual sense: a construct or protein or virus resulting from the combination of genes from two or more different sources, in which the different parts of the chimera function together. The genes are fused, where necessary in-frame, in a single genetic construct.
- chimeric refers specifically to recombinant influenza-derived nucleic acids or proteins or virions, e.g., as described by Hoffmann et al. (Proc. Natl. Acad. Sci. USA 2000, 97:6108).
- infectious refers to the ability of a virus to replicate in a cell and produce viral particles. Infectivity can be evaluated either by detecting virus, i.e., viral load, or by observing disease progression in the animal. Influenza virus (viral load) can be detected by the presence of viral negative strand RNAs and/or positive strand replication intermediates, e.g., detected by RT-PCR or direct hybridization techniques. It can also be detected, if present in sufficient amount, by the presence of replicon-derived proteins, e.g., detected by immunoassay or biochemical techniques.
- a culture medium isolated from a cell line supporting viral replication or extracts/samples from an animal are used to infect naive cells in culture.
- the important aspects of the determination of viral infectivity in vivo is the development of either an acute or chronic viral infection, which, in turn, may include either overt pathology or merely replication and propagation of the virus.
- viral load or "viral titer” is used herein to refer to a quantitative amount of virus in a cell culture or in an infected animal.
- titer can be also used to refer to a quantitative amount of virus-derived replicons produced within a susceptible cell.
- a cell line is considered to produce "high titers of virus” when, upon infection with virus or transduction with a viral replication system, it produces more infectious virions than MDCK cells as determined by number of particles, number of plaque-forming units (PFU), tissue culture infectious dose TCID 50 or logio TCID 50 value (with or without trypsin treatment), or other quantitation of virion production.
- a high viral titer means greater than 5.0 logio TCID 5 0, preferably greater than 5.5 logio TCID 50 , and more preferably greater than 6.0 logio TCID 50 .
- a high titer refers to value shown in Table 1 , 2, or 3 infra.
- Disease progression refers to the course of disease or symptoms of an infected animal, and may include acute or chronic disease symptoms.
- Pathothogenesis is a particular indication of a disease progression, and refers to the pathogenic effects of viral infection, including morbidity and mortality.
- an “individual” or “subject” or “animal”, as used herein, refers to vertebrates that support a negative strand RNA virus infection, specifically influenza virus infection, including, but not limited to, birds (such as water fowl and chickens) and members of the mammalian species, such as canine, feline, rodent (racine, murine, lupine, etc.), equine, bovine, ovine, caprine, porcine species, and primates, the latter including humans.
- birds such as water fowl and chickens
- members of the mammalian species such as canine, feline, rodent (racine, murine, lupine, etc.), equine, bovine, ovine, caprine, porcine species, and primates, the latter including humans.
- a "biological sample” refers to a sample of tissue or fluid isolated from an individual, including but not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal and genitourinary tracts, tears, saliva, milk, blood cells, tumors, organs, and also samples of in vitro cell culture constituents (including, but not limited to, conditioned medium resulting from the growth of cells in cell culture medium, putatively viral infected cells, recombinant cells, and cell components).
- an "in vitro cell system” or an “extracorporeal cell system” refers to cells which are replicated outside of the body, i.e., cell systems not found in nature; as such, the term includes primary cultures and cell lines.
- Primary cultures refers to a culture of cells that is directly derived from cells or tissues from an individual, as well as cells derived by passage from these cells, but not to immortalized cells.
- cell line refers to a population of cells capable of continuous or prolonged growth and division in vitro.
- the term “cell line” also includes immortalized cells.
- host cell means any cell of any organism that is selected, modified, transformed, grown, or used or manipulated in any way, for the production of wild-type or recombinant negative strand RNA virions, or virus-derived polypeptides.
- a preferred host cell of the present invention is a porcine cell lung epithelial cell, specifically SJPL cell.
- Other exemplary host cells include chicken lung epithelial cells and lung epithelial cells from other species.
- the host is not a mink lung epithelial cell, especially one that produces poor viral titers.
- transfection means the introduction of a foreign nucleic acid into a cell.
- the introduced gene or sequence may also be called a “cloned” or “foreign” gene or sequence, may include regulatory or control sequences, such as start, stop, promoter, signal, secretion, or other sequences used by a cellular molecular machinery.
- a host cell that receives and expresses introduced DNA or RNA has been "transfected” and is a "transfectant” or a
- transfection if a transfection of influenza-derived nucleic acid results in its subgenomic replication and influenza-derived protein expression, the transfection is termed "productive".
- antibody includes both monoclonal and polyclonal antibodies. Additionally, single polypeptide chain antigen-binding proteins, see U.S. Pat. No. 4,946,778, are included within the term “antibody”.
- a “protective immunological response” comprises a humoral (antibody) or cellular component, or both, effective to eliminate virions and infected cells in an immunized (vaccinated) subject.
- a protective immune response can prevent or resolve a negative strand RNA virus, e.g., influenza virus, infection.
- the antigens are "surface antigens", i.e., expressed on the surface of the virion or the surface of infected cells. More preferably, the surface antigens are glycoproteins.
- the primary glycoprotein antigens are hemagluttinin (HA) and neuraminidase (NA).
- immunogenic means that the polypeptide is capable of eliciting a humoral or cellular immune response, and preferably both.
- An immunogenic entity is also antigenic.
- An immunogenic composition is a composition that elicits a humoral or cellular immune response, or both, when administered to an animal.
- a molecule is "antigenic” when it is capable of specifically interacting with an antigen recognition molecule of the immune system, such as an immunoglobulin (antibody) or T cell antigen receptor.
- An antigenic polypeptide contains an "epitope" of at least about five, and preferably at least about 10, amino acids.
- An antigenic portion of a polypeptide can be that portion that is immunodominant for antibody or T cell receptor recognition, or it can be a portion used to generate an antibody to the molecule by conjugating the antigenic portion to a carrier polypeptide for immunization.
- a molecule that is antigenic need not be itself immunogenic, i.e., capable of eliciting an immune response without a carrier.
- a virus-specific vaccine is a composition that can elicit protective immunity to a virus when administered to a subject.
- the term “vaccine” refers to a composition containing virus, inactivated virus, attenuated virus, split virus, or viral protein, i.e., a surface antigen, that can be used to elicit protective immunity in a recipient (see Furminger, In: Nicholson, Webster and Hay (eds.), Textbook of Influenza, Chapter 24, pp. 324-332, particularly pp. 328-329).
- a vaccine of the invention can elicit immunity in a portion of the population, as some individuals may fail to mount a robust or protective immune response, or, in some cases, any immune response. This inability may stem from the individual's genetic background or because of an immunodeficiency condition (either acquired or congenital) or immunosuppression (e.g., treatment with immunosuppressive drugs to prevent organ rejection or suppress an autoimmune condition). Efficacy of anti-viral vaccines of the invention can be established in animal models.
- a "protective dose" of a vaccine is an amount, alone or in conjunction with an adjuvant, effective to elicit a protective immune response in a recipient subject. Protection can also depend on the route of administration, e.g., intramuscular (preferred for an inactivated vaccine) or intranasal (preferred for an attenuated vaccine).
- terapéuticaally effective dose or amount refers to that amount of a compound or compositions that is sufficient to result in a desired activity.
- pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
- carrier refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered.
- Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
- Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E.W. Martin, 18 th Edition.
- an isolated biological material can be free of some or all cellular components, i.e., components of the cells in which the native material occurs naturally (e.g., cytoplasmic or membrane component). A material shall be deemed isolated if it is present in a cell extract or supernatant.
- an isolated nucleic acid includes a PCR product, an isolated mRNA, a cDNA, or a restriction fragment.
- an isolated nucleic acid is preferably excised from the chromosome in which it may be found, and more preferably is no longer joined or proximal to non-coding regions (but may be joined to its native regulatory regions or portions thereof), or to other genes, located upstream or downstream of the gene contained by the isolated nucleic acid molecule when found in the chromosome.
- the isolated nucleic acid lacks one or more introns. Isolated nucleic acid molecules include sequences inserted into plasmids, cosmids, artificial chromosomes, and the like, i.e., when it forms part of a chimeric recombinant nucleic acid construct.
- a recombinant nucleic acid is an isolated nucleic acid.
- An isolated protein may be associated with other proteins or nucleic acids, or both, with which it associates in the cell, or with cellular membranes if it is a membrane-associated protein.
- An isolated organelle, cell, or tissue is removed from the anatomical site in which it is found in an organism.
- An isolated material may be, but need not be, purified.
- purified refers to material that has been isolated under conditions that reduce or eliminate the presence of unrelated materials, i.e., contaminants, including native materials from which the material is obtained.
- a purified virion is preferably substantially free of host cell or culture components, including tissue culture or egg proteins, non-specific pathogens, and the like.
- substantially free is used operationally, in the context of analytical testing of the material.
- purified material substantially free of contaminants is at least 50% pure; more preferably, at least 90% pure, and more preferably still at least 99% pure. Purity can be evaluated by chromatography, gel electrophoresis, immunoassay, composition analysis, biological assay, and other methods known in the art.
- Viral particles can be purified by ultrafiltration or ultracentrifugation, preferably continuous centrifugation (see Furminger, supra). Other purification methods are possible and contemplated herein.
- a purified material may contain less than about 50%, preferably less than about 75%, and most preferably less than about 90%, of the cellular components, media, proteins, or other nondesirable components or impurities (as context requires), with which it was originally associated.
- the term "substantially pure” indicates the highest degree of purity which can be achieved using conventional purification techniques known in the art.
- the term “about” or “approximately” means within a statistically meaningful range of a value. Such a range can be within an order of magnitude, preferably within 50%, more preferably within 20%, more preferably still within 10%, and even more preferably within 5% of a given value or range.
- the allowable variation encompassed by the term “about” or “approximately” depends on the particular system under study, and can be readily appreciated by one of ordinary skill in the art.
- routine techniques apply to the preparation of a cell culture of the invention, preparation (i.e., purification and isolation) of natural or recombinant virus, detection of viral replicons and antigens, isolation of viral gene segment cDNA clones, insertion of such cDNAs into plasmids, and transfection or infection of host cells with the virus.
- routine techniques of site-directed mutagenisis or gene modification permit modification of viral genes to develop attenuated or defective virus, as set forth below, or to obtain viral proteins that incorporate novel epitopes.
- the present invention in addition to cell line SJPL deposited with the American Type Culture Collection (ATCC) on April 5, 2001, and assigned Accession No. PTA-3256, provides for generating cell lines having the characteristics of SJPL.
- Normal lung tissue can be digested, e.g., with trypsin, to form a single cell suspension.
- the cells can be suspended at an appropriate cell density, i.e., a cell density that permits growth without excessive crowding, transformation, or metabolic distress; for example, about 5 x 10 cells per ml is an appropriate cell density.
- the cell suspension is added to a tissue culture flask, plate, or other container, preferably coated with collagen. Tissue culture medium is selected to support cell viability and growth.
- a buffered cell culture medium is an isotonic buffered aqueous solution, such as phosphate buffered saline (PBS), Tris-buffered saline, or HEPES-buffered saline.
- PBS phosphate buffered saline
- Tris-buffered saline Tris-buffered saline
- HEPES-buffered saline phosphate buffered saline
- the medium is Dulbecco's modified Eagle's medium (DMEM).
- tissue culture media can also be used, including basal medium Eagle (with either Earle's or Hank's salts), Iscove's modified Dulbecco's medium (IMDM), Medium 199, Minimal Essential Medium (MEM), Eagle (with Earle's or Hank's salts), RPMI, Dulbecco's phosphate buffered salts, Earle's balanced salts (EBSS), Hank's medium (not containing phenol red), and Hank's Balanced Salts (HBSS).
- basal medium Eagle with either Earle's or Hank's salts
- IMDM Iscove's modified Dulbecco's medium
- MEM Minimal Essential Medium
- Eagle with Earle's or Hank's salts
- RPMI Dulbecco's phosphate buffered salts
- EBSS Earle's balanced salts
- HBSS Hank's medium (not containing phenol red)
- HBSS Hank's Balanced Salts
- These media can be supplemented, e.g., with serum (e.g., about 5% to about 15%, preferably about 10%, fetal bovine serum or other mammalian serum, preferably free of endotoxins and other contaminants), glucose, Ham's nutrients, antibiotics, antimycotic agents, non-essential amino acids, reducing agents, HEPES, etc. If desired, serum-free medium can also be sued. Other components, such as sodium bicarbonate and L-glutamine, can be specifically included or omitted. Media, salts, and other reagents can be purchased from numerous sources, including Sigma, Gibco BRL, Life Technologies, Mediatech, and other companies.
- a lung epithelial cell line of the invention preferably establishes itself spontaneously, it is possible to use transforming factors, such as radiation and chemicals (but preferably not viruses) to create a cell line capable of continuous growth in culture.
- a cell line of the invention can be cultured continuously, with cell passaging at appropriate intervals, e.g., about 7 days, preferably about 3-4 days.
- Suitable culture conditions will depend, in part, on the preferences of the cells and the nature of the culture medium, but will generally be selected for effective cell growth. Such conditions include temperature (usually about 37°C) and atmosphere (usually humid, with about 5% to about 15% C0 2 and normal air; the C0 2 concentration is set to maintain pH for the specific culture medium and buffer characteristics).
- Cell passaging may involve trypsinization (or other mechanical or enzymatic treatment) to release the cells. Collagen may be omitted from the tissue culture vessel after the second or later passage.
- Sources of lung tissue include, but are not limited to, human, porcine, canine, feline, avian (particularly chicken, turkey, duck, goose, and other fowl), borine, ovine, caprine, equine, rodent, mustelidae (including mink, provided however that the cell line developed has the characteristics of the SJPL cell line), etc.
- the invention provides lung epithelial cell lines for each of these classes, families or genera, with the proviso that the lung epithelial cell line is not a mink lung epithelial cell line unless the mink lung epithelial cell line has the characteristics of SJPL, preferably all the characteristics of SJPL.
- Virus Production provides an efficient and economic strategy for production of vaccines for treating or viral infections, in particular, negative strand RNA virus infections.
- a lung epithelial cell line of the invention provides high titers of replicated virus and/or virus-derived antigens. These viruses and/or antigens are suitable for, and included in, virus vaccines of the invention, for which the replicated virus is inactivated and/or attenuated.
- the invention thus provides replicated influenza viruses and vaccines that have substantially similar antigenicity to the viral clinical isolates, relative to chicken egg-grown viruses, where selection pressures in the eggs change the viruses' antigenicity from that of the clinical isolates, such as through mutation of the HA gene.
- replicated influenza viruses and vaccines of the present invention provide (i) substantially similar antigenicity to the clinical isolate; (ii) consistently high titers; (iii) lack of contamination by adventitious agents, and (iv) consistent cell growth qualities.
- Influenza virus vaccines of the invention can include at least one replicated virus strain (e.g., 1-50 strains) of a mammalian influenza virus A or B.
- these vaccines may be derived from recombinant constructs, e.g., as described by Neumann et al. (Proc. Natl. Acad. Sci. USA 1999, 96:9345), Fodor et al. (J. Virol. 1999, 73:9679), or preferably Hoffmann et al. (Proc. Natl. Acad. Sci. USA 2000, 97:6108; U.S. Provisional Patent Application Serial No.
- the present invention encompasses the use of an eight-plasmid DNA transfection system for the rescue of infectious RNA virus (e.g. , influenza virus) from cloned cDNA.
- infectious RNA virus e.g. , influenza virus
- viral cDNA is inserted between the RNA polymerase I promoter and terminator sequences.
- This entire polymerase I transcription unit is flanked by an RNA polymerase II promoter and a polyadenylation site. The orientation of the two transcription units allows the synthesis of negative-sense viral RNA and positive-sense mRNA from one viral cDNA template.
- preferred viral gene segments useful in the plasmid-based system of the invention encode viral polymerase complex proteins, M proteins, and/or NS proteins from a strain well adapted to grow in cell culture or from an attenuated strain, or both.
- the eight-plasmid virus productuion system may be also used to generate single and quadruple reassortant viruses.
- a preferred "reassortment" virus of the invention is a virus in which gene segments encoding antigenic proteins from a pathogenic virus strain are combined with gene segments encoding viral polymerase complex or other similar genes (e.g. , non- glycoprotein genes, including M genes and NS genes) from viruses adapted for growth in culture (or attenuated viruses).
- the reassortment virus thus carries the desired antigenic characteristics in a background that permits efficient production in a host cell.
- Such a reassortment virus is a desirable "virus seed" for production of virions to produce vaccine (see Furminger, supra).
- the lung epithelial cell line of the invention can be either infected with virus or transfected with virus-encoding plasmid constructs.
- virus-encoding plasmid constructs For example, for the production of an inactivated influenza vaccine, six plasmids containing the non- glycoprotein segments from a high yield strain (e.g., PR/8/34 (HlNl) or WSN/33 (HlNl)) can be co-transfected with two expression plasmids containing the HA and NA cDNA of the recommended vaccine subtype. Since no helper virus is required, the generated virus is an influenza virus with the desired gene constellation.
- PR/8/34 HlNl
- WSN/33 HlNl
- PCR polymerase chain reaction
- RT-PCR reverse transcriptase-polymerase chain reaction
- Nothem blot analysis detection of virus- derived antigens (e.g. , by Westen blot, flow cytometry, or immunofluorescence) or virus- associated reporter genes.
- virions can be isolated and purified using routine techniques.
- viral particles can be purified from the cell culture medium by ultrafiltration or ultracentrifugation (see Furminger, supra).
- replicated influenza virus of the invention in isolated, purified or concentrated form, preferably has an infectivity titer of about 3 x 10 7 plaque forming units (PFU) per ml, more preferably 5 x 10 7 PFU/ml.
- infectivity titer of about 3 x 10 7 plaque forming units (PFU) per ml, more preferably 5 x 10 7 PFU/ml.
- the present invention also provides vaccine compositions comprising at least one strain of a replicated influenza virus of the present invention, in inactivated or attenuated form, optionally further comprising at least one of: (a) at least one pharmaceutically acceptable carrier or diluent; (b) at least one adjuvant and/or (c) at least one viral chemotherapeutic agent.
- Such carrier, diluent, adjuvant or chemotherapeutic agent enhances at least one immune response to at least one pathogenic influenza virus in an animal administered the vaccine composition.
- the present invention also provides a method for eliciting an immune response to at least one influenza virus strain in an animal, which response is prophylactic or therapeutic for an influenza virus infection.
- the method comprises administering to the animal a vaccine composition comprising an inactivated and/or attenuated, replicated influenza virus of the present invention.
- the composition is provided in an amount that is protective or therapeutic for the animal against a clinical influenza virus pathology caused by infection with at least one influenza A or B virus strain.
- Virus produced in accordance with the invention can be used in traditional or new approaches to vaccination (see Bilsel and Kawaoka, In: Nicholson, Webster and Hay (eds.), Textbook of Influenza, Chapter 32, pp. 422-434), particularly in the development of live, attenuated vaccines (discussed in greater detail infra).
- influenza vaccines Much effort has gone into the development of influenza vaccines (see Wood and Williams, In: Nicholson, Webster and Hay (eds.), Textbook of Influenza, Chapter 23, pp. 317- 323). While much of this section relates to influenza vaccines, the scope of the present invention extends to all anti-viral vaccines, including, but not limited to, negative strand ssRNA virus vaccines (such as Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, and Filoviridae vaccines), ambisense ssRNA virus vaccines (such as Bunyaviridae and Arenaviridae vaccines), positive strand ssRNA virus vaccines (such as Picornaviridae, Calciviridae, Togaviridae,
- negative strand ssRNA virus vaccines such as Orthomyxoviridae, Paramyxoviridae, Rhabdoviridae, and Filoviridae vaccines
- Flaviviridae, Coronaviridae, and Retroviridae vaccines such as
- Parvoviridae Parvoviridae, Papovaviridae, Adenoviridae, Herpesviridae, Poxviridae, and Iridoviridae vaccines.
- specific examples of non-influenza anti-viral vaccines of the invention for human and animal use include without limitation parainfluenza vaccines, ebola virus vaccines, West Nile virus vaccines, respiratory syncitial virus vaccines, measles vaccines, mumps vaccines, yellow fever vaccines, hepatitis A and B vaccines, herpes vaccines, foot-and-mouth disease vaccines,
- Newcastle disease vaccines porcine circovirus vaccines, and equine encephalitis vaccines.
- Three types of inactivated influenza vaccines are currently available: whole virus, split-product, and surface antigen vaccines (see Wood, In: Nicholson, Webster and Hay (eds.), Textbook of Influenza, Chapter 25, pp. 333-345). Because the present invention permits the high titer production of a desired virus, it advantageously positions a vaccine manufacturer to generate a sufficient quantity of vaccine to meet public health needs and ensure standardization, which is an important requirement currently mitigated by the need to produce clinical quantities of vaccine, usually in 8 to 9 month period (Wood, supra, p. 333).
- the lung epithelial cell line of the invention permits production of viral vaccines that are devoid of detectable non-influenza nucleic acids, heterologous viruses, or bacteria.
- Adjuvants have been used with influenza vaccines (Wood and Williams, supra).
- the term "adjuvant” refers to a compound or mixture that enhances the immune response to an antigen.
- An adjuvant can serve as a tissue depot that slowly releases the antigen and also as a lymphoid system activator that non-specifically enhances the immune response (Hood, et al,
- Adjuvants include, but are not limited to, complete Freund's adjuvant, incomplete Freund's adjuvant, saponin, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum.
- an example of a preferred synthetic adjuvant is QS-21.
- immunostimulatory proteins as described below, can be provided as an adjuvant or to increase the immune response to a vaccine.
- the adjuvant is pharmaceutically acceptable.
- Vaccination effectiveness may be enhanced by co-administration of an immunostimulatory molecule (Salgaller and Lodge, J. Surg. Oncol. 1998, 68: 122), such as an immunostimulatory, immunopotentiating, or pro-inflammatory cytokine, lymphokine, or chemokine with the vaccine, particularly with a vector vaccine.
- an immunostimulatory molecule such as an immunostimulatory, immunopotentiating, or pro-inflammatory cytokine, lymphokine, or chemokine
- cytokines or cytokine genes such as interleukin (IL)-l, IL-2, IL-3, IL-4, IL-12, IL-13, granulocyte- macrophage (GM)-colony stimulating factor (CSF) and other colony stimulating factors, macrophage inflammatory factor, Flt3 ligand (Lyman, Curr. Opin.
- immunostimulatory molecules can be delivered systemically or locally as proteins or by expression of a vector that codes for expression of the molecule.
- Inactivated Influenza Vaccines are well established for vaccinating against influenza (see Nichol, In: Nicholson, Webster and Hay (eds.), Textbook of Influenza, Chapter 27, pp. 358- 372).
- Virus can be inactivated by treatment with formaldehyde, beta-propiolactone, ether, ether with detergent (such as Tween-80), cetyl trimethyl ammonium bromide (CTAB) and Triton N101, sodium deoxycholate and tri(w-butyl) phosphate (Furminger, supra; Wood and Williams, supra). Prior to inactivation, the virions can be isolated and purified by centrifugation (Furminger, supra, see p. 326).
- the single radial immunodiffusion (SRD) test can be used (Schild et al, Bull. World Health Organ.1975, 52:43-50 and 223-31; Mostow et al, J. Clin. Microbiol. 1975, 2:531).
- the dose needed for a satisfactory immune response has been standardized and is 15 ⁇ g H A/strain/dose.
- the inactivated vaccine can be administered intramuscularly by injection.
- Attenuated cold adapted live influenza vaccines have been developed (see Keitel and Piedra, In: Nicholson, Webster and Hay (eds.), Textbook of Influenza, Chapter 28, pp. 373- 390; Ghendon, In: Nicholson, Webster and Hay (eds.), Textbook of Influenza, Chapter 29, pp. 391-399).
- the ability to generate influenza virus using reverse genetics entirely from eight plasmids allows adjustment of the attenuation of a vaccine strain and enables development of a vaccine strain optimally suited for any target population (see, Bilsel and Kawaoka, supra; Hoffmann et al, Proc. Natl. Acad. Sci. USA 2000, 97:6108). It is expected that the genetic modification of the coding or noncoding region of the internal genes improves the safety, infectivity, immunogenicity and protective efficacy of the vaccine, in addition to permitting development of attenuated virus.
- the manipulation of the HA gene can also increase the safety of a vaccine strain.
- removal of basic amino acids found in the connecting peptide of H5 or H7 glycoproteins of highly pathogenic avian influenza A viruses can increase the safety of the vaccine.
- Mucosal vaccine strategies are particularly effective for many pathogenic viruses, since infection often occurs via the mucosa.
- the mucosa harbors dendritic cells, which are important targets for influenza vaccines and immunotherapy.
- mucosal vaccination strategies for inactivated and attenuated virus vaccines are contemplated. While the mucosa can be targeted by local delivery of a vaccine, various strategies have been employed to deliver immunogenic proteins to the mucosa.
- the vaccine can be administered in an admixture with, or as a conjugate or chimeric fusion protein with, cholera toxin, such as cholera toxin B or a cholera toxin A/B chimera (Hajishengallis, J Immunol., 154:4322-32, 1995; Jobling and Holmes, Infect Immun., 60:4915-24, 1992).
- cholera toxin such as cholera toxin B or a cholera toxin A/B chimera
- Mucosal vaccines based on use of the cholera toxin B subunit have been described (Lebens and Holmgren, Dev. Biol. Stand. 82:215-27, 1994).
- an admixture with heat labile enterotoxin (LT) can be prepared for mucosal vaccination.
- mucosal immunization strategies include encapsulating the virus in microcapsules (U.S. Patents No. 5,075,109, No. 5,820,883, and No. 5,853,763) and using an immunopotentiating membranous carrier (WO 98/0558). Immunogenicity of orally administered immunogens can be enhanced by using red blood cells (rbc) or rbc ghosts (U.S. Patent No. 5,643,577), or by using blue tongue antigen (U.S. Patent No. 5,690,938).
- rbc red blood cells
- rbc ghosts U.S. Patent No. 5,643,577
- blue tongue antigen U.S. Patent No. 5,690,938.
- the invention By providing a method for producing influenza-derived antigens in lung epithelial cells, the invention also provides a method for producing novel polyclonal antibodies to influenza-derived proteins and/or viral particles comprising administering an immunogenic amount of influenza-derived proteins isolated from the cell cultures described above to an animal, and isolating generated anti-influenza antibodies.
- a further method for producing antibodies to influenza comprises screening a human antibody library for reactivity with influenza-derived proteins of the invention and selecting a clone from the library that expresses a reactive antibody.
- novel anti-influenza antibodies disclosed herein may be used diagnostically, e.g., to detect the presence and/or propagation of influenza in a cell culture or in an animal.
- these antibodies may be used therapeutically, e.g., in passive immunotherapy.
- the invention also provides a test kit for influenza diagnostics comprising anti-influenza antibodies, influenza virus components and a lung epithelial cell line permissive for influenza replication and expressing these components.
- the present invention further advantageously provides methods for screening for agents capable of modulating influenza infection and/or replication and/or virion assembly.
- Such methods include administering a candidate agent to the influenza-propagating lung epithelial cell line of the invention, and testing for an increase or decrease in a level of influenza replication or influenza-associated protein expression compared to a level of influenza replication or influenza- associated protein expression in a control untreated cell line (e.g., in the same cell line prior to administration of the candidate agent), wherein a decrease in the level of influenza replication or influenza-associated protein expression is indicative of the inhibitory activity of the agent.
- Agent-mediated inhibition of virion formation can be detected microscopically (performed directly or after immunostaining); and changes in infectivity of generated influenza virus particles can be assayed by isolating them from the cell culture medium and applying to naive cells or a susceptible animal model.
- influenza-replicating lung epithelial cell line of the present invention provides a convenient system for high-throughput initial screening of potential anti-influenza therapeutics.
- high-throughput screening system involves applying test compounds to the lung epithelial cell microcultures supporting influenza replication (growing, e.g., in 96- or 324-well microtiter plates) followed by measuring changes (e.g., using multi-plate readers or scanners) in influenza replication and/or influenza-associated protein expression and/or influenza infectivity.
- candidate therapeutic compounds include without limitation small molecule enzyme inhibitors (e.g., chelating agents), inhibitory peptides, inhibitory (e.g., transdominant-negative) proteins, antibodies, ribozymes, and antisense nucleic acids.
- small molecule enzyme inhibitors e.g., chelating agents
- inhibitory peptides e.g., inhibitory peptides
- inhibitory e.g., transdominant-negative proteins
- antibodies e.g., ribozymes
- antisense nucleic acids e.g., antisense nucleic acids.
- the anti-influenza therapeutic compounds identified using the initial in vitro screening methods of the present invention can be further characterized for their ability to affect influenza propagation using secondary screens in cell cultures and/or susceptible animal models.
- a preferred animal model of the present invention is a pig, or even more preferably a minipig.
- Test animals will be treated with the candidate compounds that produced the strongest inhibitory effects in cell culture-based assays (control animals would not be treated, and, if available, a positive control could also be employed).
- a compound that protects animals from infection by the virus and/or inhibits viral propagation leading to pathogehicity, would be an attractive candidate for development of an agent for treatment prevention of influenza infection.
- the animal models provide a platform for pharmacokinetic and toxicology studies.
- a porcine lung epithelial cell line was spontaneously established from the normal lungs of a 4-week-old female Yorkshire pig. Briefly, approximately 5g of normal lung tissue from a 4-week-old pig was digested with 30 ml lx trypsin-EDTA containing 0.5g porcine trypsin and 0.2g Na-EDTA per liter of HBSS (Sigma Chemical Co., St. Louis, MO) at 37°C. 5 x 10 5 cells per ml were plated on a tissue culture flask (75 cm 2 ) which was pre-coated with 0.01% of collagen solution (Sigma) with Dulbecco's modified Eagle's medium (DMEM; Life
- DMEM Dulbecco's modified Eagle's medium
- FBS fetal bovine serum
- MEM nonessential amino acids
- antibiotic-antimycotic solution Sigma.
- Cells were passaged at an interval of 3-4 days using 1 x trypsin-EDTA (Life Technologies) until cells were established for continuous growing. Starting from the second passage, collagen coating was not used.
- SJPL cell line was continuously cultured in DMEM supplemented with 10% FBS, 1% sodium pyruvate, 1% L-glutamine, 1.4% MEM nonessential amino acids, and 1% antibiotic- antimycotic solution.
- EXAMPLE 2 Influenza Virus Production in SJPL Porcine Lung Epithelial
- An epithelial cell line (SJPL) was spontaneously established from the normal lungs of a 4-week-old pig as described in Example 1 , above.
- MDCK cells were received from the National Institute of Medical Research (Mill Hill, UK) and were cultivated in Eagles' minimal essential medium containing 5% heat-inactivated FBS at 37°C in 5% C0 2 .
- Mink lung epithelial cells (MvlLu [ATCC Accession No.CCL-64]) were obtained from the American Type Culture Collection (Manassas, VA) and were cultivated in Eagles' minimal essential medium containing 1.5 g/L sodium bicarbonate, 0.1 mM nonessential amino acids, 1.0 mM sodium pyruvate, and 10% heat-inactivated FBS at 37°C. Because of their sensitivity to trypsin, MvlLu cells were not used to study replication efficiency.
- MvlLu cells were detached from tissue- culture flask 18 h after cells were infected with influenza viruses, even when the cells were in the presence of 0.5 ⁇ g/ml L-l-tosylamide-2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin (Worthington Biochemical Corporation, Lakewood, NJ).
- TPCK L-l-tosylamide-2-phenylethyl chloromethyl ketone
- influenza viruses used in this study were obtained from the repository at St. Jude Children's Research Hospital. All viruses were grown in 1 1 -day-old embryonated eggs, and 10-fold serial dilutions of the viruses were titrated in eggs before the viruses were used in replication efficiency experiments.
- the influenza virus used in the antigenic stability study was grown in and isolated from MDCK and SJPL cells. The original virus was from a patient's saliva gargle sample in Memphis, TN, during 1999.
- Virus titration SJPL and MDCK cells (5 x 10 5 per well) were seeded in six-well tissue-culture plates and allowed to grow to confluence. Cells were washed with phosphate- buffered saline (PBS, pH 7.2) twice and infected with 10 EID 50 (i.e., 10 times the virus dose that will infect 50% of the eggs in a population) for 1 hour at 37 °C in a humidified incubator containing 5% C0 2 . Infected cells were washed twice with warm PBS (pH 7.2), and 2 ml of medium (DMEM for SW-00 and MEM for MDCK cells) containing 1 ⁇ g/ml TPCK-treated trypsin was added to each well. Supernatants containing viruses were collected 50 hours after infection for virus titration.
- PBS phosphate- buffered saline
- MDCK cells were used for titration of MDCK-grown virus
- SJPL cells were used for titration of SJPL-grown virus.
- Supernatants from virus-infected cells were serially diluted 10-fold in medium (DMEM for SJPL-grown virus and MEM for MDCK-grown virus) containing 0.3% bovine serum albumin (BSA) and 1 ⁇ g/ml TPCK-trypsin, and 0.1 ml of the dilutions was added to four replicate wells in a 96-well plate. Seventy-two hours after infection, the presence of virus was determined by HA with 0.5% chicken red blood cells. The virus titers were expressed in units of logio TCIDso/ml.
- Influenza viruses A Sydney/5/97(H3N2), B/Memphis/1/84, and A/Swine/IA/17672/88 (HlNl) were titrated in eggs by using serial 10-fold dilutions.
- Monolayers of SJPL and MDCK cells in a 6-well plate were infected with 10 EID 50 of each virus. Infected cells were washed three times with warm PBS (pH 7.2), and medium containing 0.3% BSA and 1 ⁇ g/ml TPCK-treated trypsin was added to each well. The cells were incubated at 37°C in a 5% C0 2 . At different times after infection, 50 ⁇ l of supernatant was removed. The presence of viruses in supernatant was determined by titration as described in the preceding section.
- PCR products were purified with the QIAquick PCR purification kit (Qiagen) and sequenced by staff members in the Hartwell Center for Bioinformatics and Biotechnology at St. Jude Children's Research Hospital. They used BigDye Terminator Cycle Sequencing Ready Reaction Kits with AmpliTaq DNA polymerase, FS (Perkin-Elmer, Applied Biosystems, Inc., Foster City, CA) and synthetic olignucleotides. Analysis and translation of nucleotide sequence data were performed with the Lasergene sequence analysis software package (DNASTAR, Madison, WI). Indirect immunofluorescence assay and analysis ofcytopathic effect (CPE).
- Qiagen QIAquick PCR purification kit
- FS Perkin-Elmer, Applied Biosystems, Inc., Foster City, CA
- CPE Indirect immunofluorescence assay and analysis ofcytopathic effect
- SJPL cells were cultured to confluence in Lab-Tek chamber slides (Nalge Nunc International, Naperville, IL). Cells were washed with PBS (pH 7.2) and infected with an H3N2 (A/Sydney/5/97) influenza virus (multiplicity of infection [m.o.i.], 5) forl h at 37°C in a humidified incubator containing 5% C0 2 . Infected cells were washed twice with warm PBS (pH 7.2); DMEM containing 0.3% BSA was added to each chamber. Infected cells were incubated overnight at 37°C in the humidified incubator containing 5% C0 2 before they were fixed with 80% cold acetone in water.
- the fixed cells were incubated on ice with an anti-mouse monoclonal antibody to nucleoprotein of influenza A virus for 30 min and then washed three times with cold PBS (pH 7.2) containing 0.05% Tween 20.
- Cells were incubated on ice with fluorescein isothiocyanate (FITC)-labeled goat anti-mouse IgG for 30 min, washed four times with cold PBS (pH 7.2) containing 0.05% Tween 20, and then evaluated by using a fluorescence microscope.
- FITC fluorescein isothiocyanate
- CPE cytopathic effect
- SJPL cells, MvlLu cells, and MDCK cells trypsinized and resuspended at a concentration of IO 7 cells per ml in the binding medium (Tris-buffered saline, pH 7.6; 0.5% BSA; and ImM Ca 2+ , ImM Mg 2+ , and ImM Mn 2+ ).
- SJPL cells (3 x IO 6 ) and MDCK cells (3 x IO 6 ) were incubated for 30 min at room temperature with DIG-labeled lectins Maackia amurensis agglutinin (MAA), which specifically binds to Sia2-3Gal, or Sambucus nigra agglutinin (SNA), which specifically binds to Sia2-6Gal.
- MAA Maackia amurensis agglutinin
- SNA Sambucus nigra agglutinin
- the cells were washed three times with cold PBS (pH 7.2) containing 0.05% Tween 20, and the fluorescence intensity of the cells was analyzed with a FACS Calibur Fluorospectrometer (Becton Dickinson).
- Annexin-V-FLUOS staining propidium iodide staining, and flow cytometric analysis.
- Approximately 5 x IO 6 MDCK cells and 5 x IO 6 SJPL cells were infected with A/Sydney/5/97 (H3N2) (m.o.i., 5); we collected cells by trypsinizing them 10 h after infection.
- Annexin-V-FLUOS staining and flow cytometric analysis were performed according to the manufacturer's instructions (Roche Molecular Biochemicals). Briefly, 1 x IO 6 cells were incubated with 100 ⁇ l staining solution prepared in lOOO ⁇ l HEPES buffer added with 20 ⁇ l
- A/Swine/IA/17672/88 (HlNl) influenza viruses (m.o.i. 5), and cells were harvested 18 hours after infection.
- the harvested cells were washed in PBS and resuspended in 500 ⁇ l ice-cold lysis buffer (10 mM Tris, pH 7.5; 0.5% Triton X-100 [Sigma]) before they were incubated on ice for 30 min.
- the lysates were centrifuged for 10 min at 12,000 x g at room temperature to remove cellular debris, and the supernatant were extracted once with buffered phenol and once with buffered phenol-chloroform. DNA in the supernatant was collected by ethanol precipitation with 3 M sodium acetate (pH 5.2).
- DNA was dissolved in 20 ⁇ l sterile water, treated with RNase A (Sigma), and subjected to electrophoresis through 2% agarose (GTG SeaKem agarose; FMC BioProducts, Rockland, Maine) in TAE buffer (0.04 M Tris-acetate, pH 7.2; 0.001 M EDTA). The gel was stained with ethidium bromide. A 100-bp DNA ladder (Promega Corporation, Madison, WI) was used as a molecular marker.
- Reverse transcriptase assay To determine whether SJPL cells express procine endogenous retrovirus, a non-radioactive reverse-transcriptase assay was performed as described by the manufacturer (Roche Molecular Biochemicals). Briefly, 10 ml of supernatant from confluent SJPL cells in 75-cm 2 tissue-culture flasks was collected and subjected to ultracentrifugation (100,000 x g) for 30 min.
- Pellets were resuspended in 40 ⁇ l lysis buffer (50 mM Tris, 80 mM potassium chloride, 2.5 mM dithiothreitol [DTT], 0.75 mM EDTA, and 0.5% Triton X-100 [pH 7.8]) and incubated at room temperature for 30 min. After the pellets were completely solubilized, 20 ⁇ l of reaction mixture (46 mM Tris-HCl, 266 mM potassium chloride, 27.5 mM magnesium chloride, 9.2 mM DDT 10 ⁇ M dUTP, 10 ⁇ M dTTP, and template-primer hybrid of poly[A] and oligo[dT]) was added to tubes containing lysates.
- lysis buffer 50 mM Tris, 80 mM potassium chloride, 2.5 mM dithiothreitol [DTT], 0.75 mM EDTA, and 0.5% Triton X-100 [pH 7.8]
- HIV-1 reverse transcriptase (0.125 ng/well) served as a positive control.
- samples (60 ⁇ l) and dilutions of HIV-1 reverse transcriptase dilution (60 ⁇ l) were transferred into the wells of the microtiter plate precoated with streptavidin and incubated for 1 h at 37°C.
- 200 ⁇ l of anti-DIG-peroxidaseantibody was added to each well, and the plates were incubated for 1 h at 37°C.
- A/Sydney/5/97 (H3N2) showed strong CPE but uninfected cells showed no sign of cell damage.
- Viral titration was performed by using SJPL cells for viruses that had been grown in SPJL cells and MDCK cells for viruses that had been grown in MDCK cells.
- the titers of AJBel 42 (HlNl) and A/Port Chalmers/1/73 (H3N2) viruses were at least 100-fold higher in SJPL cells than in MDCK cells; the titers of A/PR/8/34 (HlNl), A/Japan/305/57 (H2N2), A/Korea/68 (H2N2), and B/Lee/40 viruses were at least 10-fold higher in SJPL cells than in MDCK cells.
- a Bel/42(H1N1) did not grow to detectable levels in MDCK cells, it replicated in this cell line when higher doses of this virus were used for infection.
- the replication efficiencies of equine influenza viruses were lower than those of the swine viruses in SJPL cells and in MDCK cells.
- H9N9, A/Mallard/ Alberta/223/98 (H10N8), and A/Shorebird/DE/224/97(H13N6) did not grow in MDCK cells when the cells were inoculated with a dose of 10 EID50 Higher inoculating doses of these viruses resulted in their replication in MDCK cells.
- the virus titers in MDCK cells ranged from 0.00 to 5.25 log ⁇ oTCID 50 /ml (Table 2).
- A/M4allard/Alberta/205/98 H2N9
- A/Shorebird/DE/207/98 H3N8
- A/Ruddy Turnstone/DE/69/98 H6N8
- A/Shorebird/DE/1 1 /95 H1N9
- A/M4allard/Astrakhan 263/ 82 H14N5
- A/Wedgetailed Shearwater/Western Australia/2576/79 (H15N9) viruses replicated well in SJPL cells (range of titers, 3.00 to 5.25 logi 0 TCID 50 /ml) and in MDCK cells (range of titers, 2.50 to 5.25 log ⁇ 0 TCID 5 o/ml).
- the replication efficiencies of avian influenza viruses in SJPL cells were higher than in MDCK cells (PO.0001).
- H5N1 Replication efficiencies of highly pathogenic H5N1 influenza viruses in SJPL cells.
- A/HK/156/97 (H5N1) which was originally isolated from a 3 -year-old boy, replicated well in MDCK cells and in SJPL cells; the titers ranged from 5.0 to 5.25 log ⁇ oTCID 50 /ml (Table 3).
- A/Chicken/HK 258/97 A/Chicken HK/728/97 (H5N1) virus did not grow well in either cell line.
- H5N1 Titers of A/Chicken/HK/728/97 (H5N1) were at least 10 5 -fold less than those of A/Chicken/I W258/97 (H5N1) in SJPL cells.
- the growth pattern of each virus in SJPL cells was similar to that of the same virus in MDCK cells.
- the time of peak viral growth in both SJPL and MDCK cells was 50 hours after infection, and after that time, the viral titers started to decline.
- the infectious viral titers were approximately IO 2 - to 10 3 -fold less than those at 50 hours after infection.
- detectable levels of A/Swine/IA/17672/88 HlNl
- detectable levels of B/Memphis/1/84 and A/Sydney/5/97 were not seen until 20 hours after infection.
- the mean titers of B/Memphis/1/84 and A/Sydney/5/97 were 10-fold greater in SJPL cells than in MDCK cells, whereas the mean titer of A/Swine/Lk/ 17672/88 (HlNl) at the time of peak growth (i.e., 50 hours after infection) was approximately 100-fold greater in SJPL cells than in MDCK cells.
- Table 4 Primary isolation of influenza A viruses (H3N2) from human clinical samples.
- a HA tests were performed 72 h after inoculation.
- b MDCK cells were used to determine viral titers. The titers of all 14 virus isolates were measured.
- influenza virus propagation in mammalian cells is that the growth of human influenza viruses in this type of cell usually does not lead to antigenic change; this result is in contrast to the antigenic changes that occur in influenza viruses cultured in eggs
- Human H3N2 (A/Memphis/4/99) influenza virus was passaged three times in MDCK cells, in SJPL cells, and in eggs before the nucleotide sequences were determined.
- Influenza virus receptors on SJPL cells Influenza viruses enter cells by binding to sialylglycoconjugates on the surface (Gambaryan et al, Virology, 1997, 232:345-350; Carroll et al, Virus Res., 1985, 3: 165-179; Paulson et al, The Receptors, 1985, Vol. 2, pp. 131-219; Connor et al, Virology, 1994, 205:17-234; Matrosovich et al, Virology, 1997, 233:224-234). We determined whether influenza virus receptors were present on the newly established SJPL cell line.
- Receptor specificity was evaluated by incubating the cells with DIG-labeled lectins (Maackia amurensis agglutinin [MAA], which binds specifically to Sia2-3Gal; and Sambucus nigra agglutinin [SNA], which binds specifically to Sia2-6Gal) and FITC -labeled anti-DIG antibody and then performing flow cytometric analysis. MDCK cells and MvlLu cells as well as cells stained only with the antibody, but not with lectins, were used as controls.
- DIG-labeled lectins Mela amurensis agglutinin [MAA]
- SNA Sambucus nigra agglutinin
- SJPL, MDCK, and MvlLu cells expressed Sia2-3Gal- and Sia2-6Gal- containing sialylglycoconjugates on their surface, but the numbers of receptors on the cell surface differed among the cell lines.
- the peak log intensity of Sia2-3Gal-containing receptors on the surface of MvlLu cells was 1.5, and that of Sia2-6Gal-containing receptors was 1.8, the peak log intensity of Sia2-3Gal-containing receptors on the surface of MDCK cells was 1.75, and that of Sia2-6Gal-containing receptors was 2.4, the peak log intensity of Sia2-3Gal-containing receptors on the surface of SJPL cells was 2.4, and that of Sia2-6Gal-containing receptors was 2.9. Therefore, SJPL cells have more Sia2-3Gal- and Sia2-6Gal-containing receptors than the other two cell lines.
- Influenza virus-induced damage in SJPL cells and in MDCK cells It has been reported that influenza infection of epithelial cells leads to apoptosis (Hinshaw et al, J. Virol, 1994, 68:3667-3673; Takizawa et al, J. Gen. Virol, 1993, 74:2347-2355).
- Using an Annexin-V binding assay, a propidium iodide staining assay, and a DNA fragmentation assay we determined whether influenza virus infection of the newly established porcine lung epithelial cell line also causes apoptosis.
- Annexin-V is a Ca 2+ -dependent phospholipid- binding protein with a high affinity for phosphatidylserine that translocates from the inner side of the plasma membrane to the outer side during an early stage of apoptosis but not during necrosis (Martin et al, J. Biol. Chem., 273:4345-4349, Fadok et al, J. Immunol., 1992, 148:2207-2216).
- Propidium iodide binds to DNA of necrotic cells, which have damaged membranes, but does not bind to DNA of membrane-intact apoptotic cells.
- PERV porcine endogenous retrovirus
- the SJPL cell line would not be a suitable candidate for use in influenza virus vaccine production. Because of this possibility of PERV contamination, we assayed the level of reverse transcriptase activity in tissue-culture supernatant of SJPL cells; with this assay, we could detect any type of retrovirus that was present. Reverse transcriptase activity was not detected in supernatant of SJPL cells, i.e., the levels of activity were similar to those of background (0.05 OD 4 so). In contrast, high levels of reverse transcriptase activity (1.5 OD 4 so) were detected in medium containing the positive control HIV-1 reverse transcriptase.
- PERV-specific POL PCR primers PB905 (5'CCGCAGGGATGGGTTTGGCAAAGCA3') and PB906 (5 ⁇ CGTACTGGAGGAGGGTCACCTGA3') and no virus was detected either by amplification of samples derived from tissue culture supernatant or from cellular RNAs.
- PERV-specific nucleic acid was detected in both supernatant and cellular RNA fractions of porcine kidney cell line PK-15 (ATCC Accession No. CCL-33). This cell line is known to constitutively express PERVs. Actin RNA, which was used as an internal control, was detected in all samples.
- SJPL cells expressed more Sia2-3Gal- and Sia2-6Gal-containing receptors than did MDCK or MvlLu cells. Necrosis, but not apoptosis, occurred in SJPL cells infected with influenza virus. Efforts have been made previously to find cell lines that support the productive replication of influenza virus and allow the virus to maintain its original antigenicity. African green monkey kidney (Vero) cells fully support replication of influenza A and B viruses (Govorkova et al, J. Virol., 1996, 70:5519-5524), but influenza viruses have to be extensively adapted before they can be grown in this cell line.
- influenza viruses Repeated addition of trypsin to the culture medium is also needed for multicycle growth of the influenza viruses (Kaverin et al, J. Virol., 1995, 69:2700-2703).
- BHK cells also support replication of influenza viruses, but growth in BHK cells, like that in eggs, results in the selection of receptor-binding variants of human influenza viruses (Govorkova et al, Virology, 1999, 262:31-38).
- MDCK cells are currently considered to be the best cell line for supporting the growth of influenza viruses, but this cell line causes cancer in nude mice (Govorkova et al, 1996, supra). Therefore, MDCK cells have not been licensed for use in the production of vaccines.
- Cold-adapted influenza virus vaccine can be produced in specific pathogen-free (SPF) eggs, but in a pandemic, the supply of this type of egg will not be sufficient to meet demand.
- SJPL cells for use in influenza vaccine production is that propagation of human influenza A viruses in these cells does not lead to antigenic changes in the HA molecule.
- Current vaccines prepared from human influenza viruses adapted for growth in eggs contain variants whose HA molecules differ from that of the original human virus by at least one or two amino acids (Katz et al, Virology, 1987, 156:386-395, Robertson et al, Vaccine, 1995, 13: 1583-1588). This variation will result in the immune escape of influenza viruses in the immunized humans.
- Fas Fas-ligand
- Fas-associated death domain proteins Fas-associated death domain proteins
- FADD Fas-associated death domain proteins
- caspase-8 proenzyme the death domain in the cytoplasmic portion of Fas recruits Fas-associated death domain proteins (FADD) and the caspase-8 proenzyme; these factors then participate in zip caspase activation and apoptosis (Chinnaiyan et al, Cell, 1995, 81:505-512, Kischkel et al, EMBO J., 1995, 14:5579- 5588, Huang et al, Nature, 1996, 384:638-641, Martin et al, J. Biol. Chem., 1998, 273:4345- 4349). It is possible that influenza virus infection of SJPL cells does not induce expression of Fas and FasL on the cell surface; this lack of expression may explain why uninfected SJPL cells do not undergo apoptosis.
- Mitochondria play an important role in regulating apoptosis (Green and Reed, Science, 1998, 281 : 1309-1312).
- proapoptotic factors such as cytochrome c, procaspase-2, -3, and -9, and apoptosis-inducing factor are released from the mitochondrial membrane space and are free to participate in the degradation phase of apoptosis (Liu et al, Cell, 1996, 86: 147-157, Mancini et al., ].
- NF- ⁇ B transcriptional activator nuclear factor- ⁇ B
- influenza virus infection of respiratory epithelial cells causes apoptosis or necrosis in vivo.
- influenza A virus was predominantly found in intact and detached necrotic epithelial cells of larger bronchi.
- A/Env/HK/437/99 H5N1
- foci of parenchymal cell necrosis occurred in the pancreas, brain, and heart and lymphocyte depletion and apoptosis occurred in the spleen, cloacal bursa, and thymus
- A/HK 483/97 (H5N1), apoptosis was detected in lung tissue 6 days after infection (Tumpey et al, J. Virol, 2000, 74:6105-6116). It remains to be determined whether apoptosis observed in chickens and mice is caused by the direct effect of virus replication or by bystander effects of immune responses such as those mediated by cytotoxic T lymphocytes or cytokines such as tumor necrosis factor (Zychlinsky et al, J. Immunol., 1991, 146:393-400, Larrick and Wright, FASEB J., 1990, 4:3215-3223).
- influenza virus infection results in necrosis, which causes inflammatory responses and subsequently permits the secondary bacterial infection of the respiratory tract.
- necrosis causes inflammatory responses and subsequently permits the secondary bacterial infection of the respiratory tract.
- the limited apoptosis is induced by an immune-mediated mechanism to eliminate virus from infected cells in the respiratory tract.
- SJPL cells support the efficient high titer replication of influenza viruses of different subtypes and that growth of human influenza virus in SJPL cells, unlike that in eggs, does not lead to antigenic changes in the virus.
- this novel cell line may be useful in studying influenza virus-induced damage of respiratory epithelial cells and cytokine-induced damage of respiratory epithelial cells.
- this cell line is useful in virus surveillance and in making human vaccines that can provide greater protection against infection than those vaccines currently prepared in eggs.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/477,016 US20040142450A1 (en) | 2002-05-10 | 2002-05-10 | Lung epithelial cell line for propagating viruses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29025401P | 2001-05-10 | 2001-05-10 | |
US60/290,254 | 2001-05-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002089586A1 true WO2002089586A1 (fr) | 2002-11-14 |
Family
ID=23115169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/015030 WO2002089586A1 (fr) | 2001-05-10 | 2002-05-10 | Lignee cellulaire epitheliale pulmonaire pour propagation de virus |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2002089586A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1757934A1 (fr) | 2005-08-26 | 2007-02-28 | Buddhist Tzu Chi General Hospital | Méthode de criblage pour des composés contre des flaviviruses en employant le système de cellules persistant virus-infecté |
WO2009059411A1 (fr) * | 2007-11-06 | 2009-05-14 | Valorisation-Recherche, Limited Partnership | Lignée de cellules épithéliales de poumon de porc et son utilisation dans la production et la détection du virus du syndrome reproducteur et respiratoire porcin |
US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
EP3686276A1 (fr) * | 2019-01-28 | 2020-07-29 | Freie Universität Berlin | Production de virus dans des lignées de cellules épithéliales à croissance continue dérivées de l'intestin de poulet |
US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5547932A (en) * | 1991-09-30 | 1996-08-20 | Boehringer Ingelheim International Gmbh | Composition for introducing nucleic acid complexes into higher eucaryotic cells |
-
2002
- 2002-05-10 WO PCT/US2002/015030 patent/WO2002089586A1/fr not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5547932A (en) * | 1991-09-30 | 1996-08-20 | Boehringer Ingelheim International Gmbh | Composition for introducing nucleic acid complexes into higher eucaryotic cells |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US9345758B2 (en) | 2005-04-21 | 2016-05-24 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US9913892B2 (en) | 2005-04-21 | 2018-03-13 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US10258686B2 (en) | 2005-04-21 | 2019-04-16 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US11160859B2 (en) | 2005-04-21 | 2021-11-02 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
EP1757934A1 (fr) | 2005-08-26 | 2007-02-28 | Buddhist Tzu Chi General Hospital | Méthode de criblage pour des composés contre des flaviviruses en employant le système de cellules persistant virus-infecté |
WO2009059411A1 (fr) * | 2007-11-06 | 2009-05-14 | Valorisation-Recherche, Limited Partnership | Lignée de cellules épithéliales de poumon de porc et son utilisation dans la production et la détection du virus du syndrome reproducteur et respiratoire porcin |
EP3686276A1 (fr) * | 2019-01-28 | 2020-07-29 | Freie Universität Berlin | Production de virus dans des lignées de cellules épithéliales à croissance continue dérivées de l'intestin de poulet |
WO2020157076A1 (fr) * | 2019-01-28 | 2020-08-06 | Freie Universität Berlin | Production de virus dans la croissance continue de lignées cellulaires épithéliales dérivées de l'intestin de poulet |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6352974B2 (ja) | ワクチンのための高力価組み換えインフルエンザ・ウィルス | |
JP4771959B2 (ja) | インフルエンザウイルス作製のための多重プラスミド系 | |
JP5303603B2 (ja) | インフルエンザウイルスの生産用多重プラスミドシステム | |
KR101272487B1 (ko) | 인플루엔자 바이러스의 구제 | |
CN100489107C (zh) | 用于产生感染性流感病毒的dna转染*** | |
US8802417B2 (en) | Production of viruses, viral isolates and vaccines | |
US8475807B2 (en) | Avian influenza virus live attenuated vaccine and uses thereof | |
US8597661B2 (en) | Neuraminidase-deficient live influenza vaccines | |
AU2001259211A1 (en) | DNA transfection system for the generation of infectious influenza virus | |
US11180737B2 (en) | Generation of infectious influenza viruses from virus-like particles | |
JP2012511914A (ja) | インフルエンザワクチンの生成 | |
US20140377308A1 (en) | METHOD FOR PRODUCTION OF pH STABLE ENVELOPED VIRUSES | |
US20040142450A1 (en) | Lung epithelial cell line for propagating viruses | |
WO2002089586A1 (fr) | Lignee cellulaire epitheliale pulmonaire pour propagation de virus | |
Marzio et al. | Production of viruses, viral isolates and vaccines | |
Van Doremalen | Receptor binding properties, cell tropism and transmission of influenza A virus | |
IVE | Kawa0ka et al. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10477016 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |